5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases

Abstract

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

We claim: 
     
         1 . A method for treating a disorder or disease selected from leishmaniasis, Chagas diseases and human African trypanosomiasis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof and optionally in combination with a second agent;
 wherein said compound is selected from 3-fluoro-N-(4-fluoro-3-(5-(3-(trifluoromethyl)azetidin-1-yl)-2H-pyrazolo[3,4-b]pyridin-2-yl)phenyl)azetidine-1-carboxamide;   N-(3-(5-(5-azaspiro[2.3]hexan-5-yl)-2H-pyrazolo[3,4-b]pyridin-2-yl)-4-fluorophenyl)azetidine-1-carboxamide; and   N-(2-(5-(3,3-difluoroazetidin-1-yl)-2H-pyrazolo[3,4-b]pyridin-2-yl)pyridin-4-yl)azetidine-1-carboxamide.   
     
     
         2 . The method of  claim 1 , wherein said disease is leishmaniasis selected from visceral leishmaniasis and cutaneous leishmaniasis. 
     
     
         3 . The method of  claim 2 , wherein said second agent selected from stibogluconate, meglumine antimoniate, amphotericin, miltefosine, and paromomycin. 
     
     
         4 . The method of  claim 1 , wherein said disease is Chagas disease; and said second agent is selected from benznidazole, nifurtimox and amphotericin. 
     
     
         5 . The method of  claim 1 , wherein said disease is human African trypanosomiasis; and said second agent is pentamidine, suramin, melarsoprol, eflornithine, or nifurtimox.